Pulmonx Corp Ordinary Shares LUNG
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Pulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024
-
Pulmonx to Participate in the Lake Street 8th Annual Best Ideas Growth Conference
-
Pulmonx to Present at the 2024 Wells Fargo Healthcare Conference
-
Pulmonx Reports Second Quarter 2024 Financial Results
-
Pulmonx to Present at the Canaccord Genuity 44th Annual Growth Conference
-
Pulmonx to Report Second Quarter 2024 Financial Results on July 31, 2024
Trading Information
- Previous Close Price
- $7.44
- Day Range
- $7.18–7.42
- 52-Week Range
- $5.46–14.84
- Bid/Ask
- $7.30 / $7.33
- Market Cap
- $286.99 Mil
- Volume/Avg
- 55,160 / 302,951
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.74
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 279
- Website
- https://www.pulmonx.com
Comparables
Valuation
|
Metric
|
LUNG
|
NARI
|
PRCT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 460.04 | — |
Price/Book Value | 2.88 | 5.88 | 15.63 |
Price/Sales | 3.74 | 4.52 | 21.64 |
Price/Cash Flow | — | 345.21 | — |
Price/Earnings
LUNG
NARI
PRCT
Financial Strength
|
Metric
|
LUNG
|
NARI
|
PRCT
|
|---|---|---|---|
Quick Ratio | 7.75 | 1.38 | 6.37 |
Current Ratio | 8.97 | 1.80 | 7.51 |
Interest Coverage | −16.66 | −164.83 | −26.05 |
Quick Ratio
LUNG
NARI
PRCT
Profitability
|
Metric
|
LUNG
|
NARI
|
PRCT
|
|---|---|---|---|
Return on Assets (Normalized) | −21.96% | −1.37% | −20.90% |
Return on Equity (Normalized) | −33.26% | −1.89% | −30.98% |
Return on Invested Capital (Normalized) | −25.19% | −3.24% | −25.33% |
Return on Assets
LUNG
NARI
PRCT
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| Nmbpdlzz | Xglxnq | $197.7 Bil | |||
| Stryker Corp
SYK
| Jcbltmmnwb | Fqv | $135.3 Bil | |||
| Boston Scientific Corp
BSX
| Lwkfhrcgs | Rlkwf | $124.4 Bil | |||
| Medtronic PLC
MDT
| Xvvxfqsw | Qtsct | $114.3 Bil | |||
| Edwards Lifesciences Corp
EW
| Nxzglqqzt | Qdkfp | $39.2 Bil | |||
| Koninklijke Philips NV ADR
PHG
| Jzgq | Zvmw | $30.2 Bil | |||
| DexCom Inc
DXCM
| Tdbfzsscz | Ktk | $26.9 Bil | |||
| Steris PLC
STE
| Zpwdsnng | Vjgsvd | $23.1 Bil | |||
| Zimmer Biomet Holdings Inc
ZBH
| Zggqxrskt | Zhxr | $21.5 Bil | |||
| Insulet Corp
PODD
| Yhhgyxjlk | Zxdbwr | $16.3 Bil |
United States